• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Academy
  • FAQ
  • News
  • Blog
  • Europe
    • United Kingdom
    • Spain
    • Italy
    • Portugal
    • Brazil
    • Colombia
    • Ecuador
    • Mexico
    • Argentina
    • Latin America
    • UAE
Veritas

Veritas

  • Services and Test
        • Preventive Medicine
          • myGenome
          • myGeneticRisk
          • myHealthScore
          • myPharma
        • Perinatal Medicine
          • myPrenatal
          • myNewborn
          • myBabyHealth
          • PregnancyLoss
          • PrenatalWES
        • Diagnostic Genetics Services
          • CardioRisk
          • CancerRisk
          • GenomeDx
          • ExomeDx
          • Targeted Panels
        • Genetic Counselling
          • Genetic Counselling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • CONTACT
LlámanosLlámanos
CALL US!
  • Europe

  • United Kingdom

  • Spain

  • Italy

  • Brazil

  • Portugal

  • Colombia

  • Ecuador

  • Mexico

  • Argentina

  • Latin America

  • Services & Test
    • Preventive Medicine
      • myGenome
      • myGeneticRisk
      • myHealthScore
    • Pregnancy & Early Childhood
      • myPrenatal
      • myNewborn
      • myBabyHealth
      • PregnancyLoss
    • Genetics Diagnostics
      • CardioRisk
      • CancerRisk
      • GenomeDx
      • ExomeDx
      • Targeted Panels
    • Genetic Counseling
  • Medical Professionals
  • Partners
  • Experiences
  • About Veritas
  • Academy
  • FAQ
  • News
  • Blog
  • Contact

News

Veritas reinforces commitment to precision in Gynaecological Cancer Care at BGCS Annual Scientific Meeting 2025

July 14, 2025

Veritas drives genomic innovation and showcases pioneering research at European Human Genetics Conference 2025 in Milan

May 29, 2025

Veritas highlights value in cancer and prevention at UK cancer genetics group spring meeting

May 13, 2025

Driving genomic innovation: Veritas’s impact at the Festival of Genomics

January 30, 2025

Veritas Genetics reaches an agreement with Apposite Capital and other shareholders, for the full acquisition of NIMGenetics, leading the future of medical genetics

January 16, 2025

Veritas Genetics participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients

October 4, 2024

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 8
  • »

Footer

  • facebook
  • youtube
  • twitter
  • instagram
  • linkedin

VERITAS INTERCONTINENTAL – CALLE ORENSE 58, 2ºC-D, 28020 MADRID, ESPAÑA – CIF B88132907 – AUTHORIZED MEDICAL CENTER Registration Nº CS20242

  • Privacy policy and Legal Notice
  • General contracting conditions
  • Cookies Policy